SCHEMBL299397

SCHEMBL299397

Cc1cc(F)c(C(=O)c2c[nH]c(C(=O)NCc3nnc(-c4ccn[nH]4)s3)c2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.47
MAPK7 Q13164 7/20 0.47
HTT P42858 7/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP2C9 P11712 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
MAPK11 Q15759 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607176 0.93 MAPK14 (0.48) MAPK14MAPK7HTTHPGDSMN1; SMN2
SCHEMBL298880 0.91 MAPK14 (0.58) MAPK14MAPK7HTT
SCHEMBL299039 0.81 MAPK14 (0.43) MAPK14MAPK7HTTALDH1A1LMNA
SCHEMBL605305 0.80 HDAC6 (0.31)
SCHEMBL605284 0.79 MAPK14 (0.49) MAPK14MAPK7HTTHPGDSMN1; SMN2
SCHEMBL10042087 0.78 MAPK14 (0.48) MAPK14MAPK7HTTALDH1A1LMNA
SCHEMBL606306 0.78 MAPK14 (0.42) MAPK14MAPK7HTTSMN1; SMN2L3MBTL1
SCHEMBL606459 0.78 MAPK14 (0.52) MAPK14MAPK7HTTHPGDSMN1; SMN2
SCHEMBL607684 0.78 HDAC6 (0.39) MAPK14MAPK7HTTALDH1A1LMNA
SCHEMBL10042044 0.77 MAPK14 (0.50) MAPK14MAPK7HTTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513289-B2 P38 kinase inhibiting agents MERCK SHARP & DOHME CORP. (US) 2013-08-20 US disclosed
US-8513289-B2 P38 kinase inhibiting agents MERCK SHARP & DOHME CORP. (US) 2013-08-20 US disclosed
EP-2427452-A1 P38 KINASE INHIBITING AGENTS Merck Sharp & Dohme Corp. (US) 2012-03-14 EP disclosed
US-20120040999-A1 P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME LLC 2012-02-16 US disclosed
US-20120040999-A1 P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME LLC 2012-02-16 US disclosed
WO-2010129208-A1 P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME CORP. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040999-A1 P38 KINASE INHIBITING AGENTS MAPK1, MAPK8, MAPKAPK2 MAPK14 13/4885MAPK7 4/4885HTT 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.